Skip to content


๐Ÿ”ฅ ๐๐ž๐ฐ ๐€๐ฉ๐ฉ๐ซ๐จ๐ฏ๐š๐ฅ๐ฌ that snuck in to 2023 ๐Ÿ“…

๐Ÿ‘€FDA Approves Lupinโ€™s Eye Drops for Allergic Conjunctivitis
Lupin announced they have received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Loteprednol Etabonate Ophthalmic Suspension, 0.2%. Loteprednol Etabonate #Ophthalmic Suspension, 0.2% is specifically indicted for the temporary relief of the signs and symptoms associated with seasonal allergic conjunctivitis.

๐Ÿ‘FDA Grants Orphan Drug Designation to Cellusionโ€™s CLS00 for Bullous Keratopathy.
Cellusion Inc. announced that its regenerative medicine product, known as "iPS cell-derived corneal endothelial cell substitute" (CLS001), has received orphan drug designation from the #FDA for bullous keratopathy.

Who's excited to see what new drugs and products that come to market in 2024 ๐Ÿ™‹โ€โ™‚๏ธ Remember to follow Vision Executives to stay up to date with the latest #eyecare news and vacancies.